Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

187423730e664bbdee8b07d5e3b8b7e95d5dc0edf245fd5a48138f7519b78239

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

dfbdf6c6c2adfa97f788675cc969fe1d97d9030e9d7004ceb87b091b5f48808f

b1be67785b4f177cfd358853c07bb4937afc13cd2ce2a70bcbd30ea7d0716534

36f9101ec0538e28989fe65629cbe6cfbb8d9c48218fdb74b14caa222b63c1d4

North America

- United States

Europe

Asia-Pacific

Other Regions

- Other Countries

Total Revenue

cefba07ba3cb8d5a15f02d862a5f18133c31f03d9969a0cd3d62252b0776cb5a

Organic revenue growth for Life Sciences Solutions (percent)

Organic revenue growth for Analytical Instruments (percent)

Organic revenue growth for Specialty Diagnostics (percent)

Organic revenue growth for Laboratory Products and Biopharma Services (percent)

Organic revenue growth (percent)

9a331741905ff64bb6ff8b89f4b959e628d7324cf47234e33f5b37aa2f7069d8

Product revenues (USD, millions)

Service revenues (USD, millions)

Total revenues (USD, millions)

Cost of product revenues (USD, millions)

Cost of service revenues (USD, millions)

Selling, general and administrative expenses (USD, millions)

Research and development expenses (USD, millions)

Restructuring and other costs (USD, millions)

Total costs and operating expenses (USD, millions)

Operating income (USD, millions)

Interest income (USD, millions)

Interest expense (USD, millions)

Other income/(expense) (USD, millions)

Income before income taxes (USD, millions)

Provision for income taxes (USD, millions)

Equity in earnings/(losses) of unconsolidated entities (USD, millions)

Net income (USD, millions)

Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest (USD, millions)

Net income attributable to Thermo Fisher Scientific Inc. (USD, millions)

Basic earnings per share attributable to Thermo Fisher Scientific Inc. (USD)

Diluted earnings per share attributable to Thermo Fisher Scientific Inc. (USD)

8d108a77d4affc35e09d3bd80ee57c3f35542eca24f06a2041a0bce4c07e4845

Depreciation of property, plant and equipment (USD, millions)

Amortization of acquisition-related intangible assets (USD, millions)

Change in deferred income taxes (USD, millions)

Stock-based compensation (USD, millions)

Other non-cash expenses, net (USD, millions)

Changes in assets and liabilities, excluding the effects of acquisitions (USD, millions)

Net cash provided by operating activities (USD, millions)

Purchases of property, plant and equipment (USD, millions)

Proceeds from sale of property, plant and equipment (USD, millions)

Proceeds from cross-currency interest rate swap interest settlements (USD, millions)

Acquisitions, net of cash acquired (USD, millions)

Purchases of investments (USD, millions)

Other investing activities, net (USD, millions)

Net cash used in investing activities (USD, millions)

Net proceeds from issuance of debt (USD, millions)

Repayment of debt (USD, millions)

Proceeds from issuance of commercial paper (USD, millions)

Repayments of commercial paper (USD, millions)

Purchases of company common stock (USD, millions)

Dividends paid (USD, millions)

Other financing activities, net (USD, millions)

Net cash used in financing activities (USD, millions)

Exchange rate effect on cash (USD, millions)

Decrease in cash, cash equivalents and restricted cash (USD, millions)

Cash, cash equivalents and restricted cash at beginning of period (USD, millions)

Cash, cash equivalents and restricted cash at end of period (USD, millions)

0e6135271ab631d78c255ac540c9454211dccf264ad1d0054292eefb5679241d

Cash and Cash Equivalents (USD, millions)

Accounts Receivable, less allowances (USD, millions)

Inventories (USD, millions)

Contract Assets, Net (USD, millions)

Other Current Assets (USD, millions)

Total Current Assets (USD, millions)

Property, Plant and Equipment, Net (USD, millions)

Acquisition-related Intangible Assets, Net (USD, millions)

Other Assets (USD, millions)

Goodwill (USD, millions)

Total Assets (USD, millions)

Short-term Obligations and Current Maturities of Long-term Obligations (USD, millions)

Accounts Payable (USD, millions)

Accrued Payroll and Employee Benefits (USD, millions)

Contract Liabilities (USD, millions)

Other Accrued Expenses (USD, millions)

Total Current Liabilities (USD, millions)

Deferred Income Taxes (USD, millions)

Other Long-term Liabilities (USD, millions)

Long-term Obligations (USD, millions)

Redeemable Noncontrolling Interest (USD, millions)

Common Stock (USD, millions)

Capital in Excess of Par Value (USD, millions)

Retained Earnings (USD, millions)

Treasury Stock at Cost (USD, millions)

Accumulated Other Comprehensive Income/(Loss) (USD, millions)

Total Thermo Fisher Scientific Inc. Shareholders’ Equity (USD, millions)

Noncontrolling Interests (USD, millions)

Total Equity (USD, millions)

Total Liabilities, Redeemable Noncontrolling Interest and Equity (USD, millions)

66be3318fa21c7c9d82257b72277034f14be58b36fa7b1fe8b97648b3361f16e

Thermo Fisher Scientific Inc (TMO)

Financials